South Korean well being tech firm Neurophet has obtained certification from Singapore’s Well being Sciences Authority for its AI-enabled degenerative mind illness analysis assistant software program.
Its flagship software program, Neurophet Aqua, analyses mind MRI utilizing AI to test for mind atrophy and white matter degeneration as seen in neurodegenerative ailments similar to Alzheimer’s illness and vascular dementia. The corporate claims that its product can section and analyse mind photographs inside 5 minutes with an evaluation failure charge of 0%.
WHY IT MATTERS
Neurophet seeks to enter the highly-valuable Singaporean medical business, which is forecasted to develop to about $49 billion by 2029. The corporate first entered the market with the Neurophet Scale PET, which quantitatively analyses biomarkers of Alzheimer’s illness by combining mind PET and MRI photographs. It additionally acquired the HSA approval for this late final yr.
THE LARGER TREND
The corporate is working double time to additional penetrate the higher Southeast Asian market by collaborating with the Dementia Analysis Heart below Nanyang Technological College’s Lee Kong Chian Faculty of Drugs in Singapore to conduct multidisciplinary mind illness analysis that may validate its AI software program choices.
In December, the corporate partnered with medical gadget distributor Clairvo Applied sciences to broaden entry to Neurophet Aqua within the Japanese market.